

1 QUINN EMANUEL URQUHART OLIVER & HEDGES, LLP  
Adrian M. Pruetz (Bar No. 118215)  
2 Jeffrey N. Boozell (Bar No. 199507)  
865 South Figueroa Street, 10th Floor  
3 Los Angeles, California 90017-2543  
Telephone: (213) 443-3000  
4 Facsimile: (213) 443-3100  
E-Mail: adrianpruetz@quinnemanuel.com  
5 jeffboozell@quinnemanuel.com

6 Robert W. Stone (Bar No. 163513)  
Brian C. Cannon (Bar No. 193071)  
7 T.J. Chiang (Bar No. 235165)  
555 Twin Dolphin Drive, Suite 560  
8 Redwood Shores, California 94065  
Telephone: (650) 801-5000  
9 Facsimile: (650) 801-5100  
E-Mail: robertstone@quinnemanuel.com  
10 brian cannon@quinnemanuel.com  
tjchiang@quinnemanuel.com

11 Attorneys for Defendants and Counterclaimants Roche  
12 Molecular Systems, Inc.; Roche Diagnostics Corporation;  
and Roche Diagnostics Operations, Inc.

13 UNITED STATES DISTRICT COURT  
14 NORTHERN DISTRICT OF CALIFORNIA

15 THE BOARD OF TRUSTEES OF THE LELAND  
16 STANFORD JUNIOR UNIVERSITY,

17 Plaintiff,

18 vs.

19 ROCHE MOLECULAR SYSTEMS, INC.; ROCHE  
20 DIAGNOSTICS CORPORATION; ROCHE  
DIAGNOSTICS OPERATIONS, INC.,

21 Defendants.

22 ROCHE MOLECULAR SYSTEMS, INC. ROCHE  
23 DIAGNOSTICS CORPORATION; ROCHE  
DIAGNOSTICS OPERATIONS, INC.,

24 Counterclaimants,

25 vs.

26 THE BOARD OF TRUSTEES OF THE LELAND  
27 STANFORD JUNIOR UNIVERSITY; THOMAS  
MERIGAN; AND MARK HOLODNIY;

28 Counterclaim Defendants.

CASE NO. C-05-04158 MHP

DECLARATION OF RHEA  
NERSESIAN IN SUPPORT OF  
ROCHE'S OPPOSITION TO  
COUNTERCLAIM DEFENDANTS'  
MOTION FOR SUMMARY  
JUDGMENT


**Declaration of Rhea Nersesian**

I, Rhea Nersesian, declare:

1. I have personal knowledge of the facts stated herein. If called upon to testify I could, and would, testify competently thereto.
2. I am currently a patent agent in the legal department of Roche Molecular Systems, Inc. I have previously submitted a declaration in support of Roche's Motion for Summary Judgment.
3. Roche's Amplicor HIV-1 Monitor v.1.0 kit ("Monitor kit") was first sold to the public on June 25, 1996. Attached hereto as Exhibit A is a printout identifying the customers who were shipped the Monitor kit on that day, including, on page 3, Stanford University Hospital.
4. The Food and Drug Administration ("FDA") permitted Roche to use data from research collaborations as well as data from drug trials in support of its application for FDA approval of the Monitor kit. These studies were done with a prototype of the Monitor kit.
5. Attached hereto as Exhibit B are relevant pages from Roche's submission to the FDA seeking approval of the Monitor kit. The attached pages indicate that Stanford University's Dr. Thomas Merigan was the principal investigator on one of the trials that supported Roche's application.
6. Roche requested FDA approval of the Monitor kit on November 3, 1995.
7. The FDA approved the Monitor kit for sale on June 3, 1996.
8. Attached hereto as Exhibit C is a copy of a letter dated March 19, 2003 from Stanford University's Luis Mejia to Roche Molecular Systems CEO, Heiner Dreismann.

I declare under penalty of perjury under the laws of the United States that the foregoing is true and correct.

Executed on November 15, 2006, in Alameda, California.

  
Rhea Nersesian